3 Canadian Healthcare Stocks With Up To 30% Revenue Growth
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
Wholesale inflation in the United States is running at a 6.5% annual rate, according to the latest producer price data, and central bankers keep saying policy will follow inflation. That kind of backdrop often pushes investors toward essential services. Healthcare in Canada fits
Directly affected
- No company is named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story.
- EWC iShares MSCI Canada ETF+2.0% 30d
iShares MSCI Canada ETF holds stocks listed in Canada, which this story is about (“canadian”).
- BWX SPDR Bloomberg International Treasury Bond ETF
SPDR Bloomberg International Treasury Bond ETF holds government bonds outside the US, which react to inflation and interest-rate news like this one in Canada
- EFA iShares MSCI EAFE ETF-0.7% 6d
iShares MSCI EAFE ETF is a broad fund of developed-market stocks that includes Canada
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
- PFE Pfizer+5.2% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | -0.28% | +0.04% | base | after close | after close | after close | after close |
| XBI | +4.20% | +3.78% | base | after close | after close | after close | after close |
| EWC | +1.51% | +0.68% | base | after close | after close | after close | after close |
| BWXPrices arriving within minutes | — | — | — | after close | after close | after close | after close |
| EFAPrices arriving within minutes | — | — | — | after close | after close | after close | after close |
| LLY | -2.25% | -0.49% | base | after close | after close | after close | after close |
| JNJ | -1.35% | -1.97% | base | after close | after close | after close | after close |
| PFE | +1.19% | +1.90% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
3 Canadian Healthcare Stocks With Up To 30% Revenue Growth Yahoo! Finance Canada
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| EWC | three days earlier | +0.68% | final price |
| EWC | five days earlier | +1.51% | final price |
| JNJ | three days earlier | -1.97% | final price |
| JNJ | five days earlier | -1.35% | final price |
| LLY | three days earlier | -0.49% | final price |
| LLY | five days earlier | -2.25% | final price |
| PFE | three days earlier | +1.90% | final price |
| PFE | five days earlier | +1.19% | final price |
| XBI | three days earlier | +3.78% | final price |
| XBI | five days earlier | +4.20% | final price |
| XLV | three days earlier | +0.04% | final price |
| XLV | five days earlier | -0.28% | final price |
Trades by members of Congress and officials in the stocks in this story
- Sen. John Boozman sold EFA (jointly held), worth $1,001 - $15,000 on 9 Sep 2026. That is 66 days before publication. Filed 21 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 25 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 71 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 38 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 45 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 50 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 71 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 85 days before publication. Filed 8 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “3 Canadian Healthcare Stocks With Up To 30% Revenue Growth” looks
12 out of 100
“3 Canadian Healthcare Stocks With Up To 30% Revenue Growth” scores 12 out of 100. The score uses 1 sources.